These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30838777)

  • 1. Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trials.
    Nonaka T; Igeta M; Matsui S
    Pharm Stat; 2019 Jul; 18(4):459-475. PubMed ID: 30838777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to confirmatory testing of subpopulations in clinical trials.
    Glimm E; Di Scala L
    Biom J; 2015 Sep; 57(5):897-913. PubMed ID: 26033644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of statistical analysis plans in randomize-all phase III trials with a predictive biomarker.
    Matsui S; Choai Y; Nonaka T
    Clin Cancer Res; 2014 Jun; 20(11):2820-30. PubMed ID: 24691019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint probability of statistical success of multiple phase III trials.
    Zhang J; Zhang JJ
    Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adapting the sample size planning of a phase III trial based on phase II data.
    Wang SJ; Hung HM; O'Neill RT
    Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
    Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
    Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker.
    Choai Y; Matsui S
    Biometrics; 2015 Mar; 71(1):25-32. PubMed ID: 25303178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.
    Takazawa A; Morita S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1018-1034. PubMed ID: 31989540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size planning for phase II trials based on success probabilities for phase III.
    Götte H; Schüler A; Kirchner M; Kieser M
    Pharm Stat; 2015; 14(6):515-24. PubMed ID: 26412484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the success probability of a Phase III clinical trial based on Phase II data.
    Su Z
    Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial.
    Takahashi F; Morita S
    J Biopharm Stat; 2018; 28(5):870-883. PubMed ID: 29420118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials.
    Toyoizumi K; Matsui S
    Stat Med; 2022 Nov; 41(26):5276-5289. PubMed ID: 36055340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
    Zhang YY; Ting N
    J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "RCT augmentation": a novel simulation method to add patient heterogeneity into phase III trials.
    Karcher H; Fu S; Meng J; Ankarfeldt MZ; Efthimiou O; Belger M; Haro JM; Abenhaim L; Nordon C;
    BMC Med Res Methodol; 2018 Jul; 18(1):75. PubMed ID: 29980181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.